AFT Forsyth & Company’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.37M | Hold |
6,313
| – | – | 0.65% | 37 |
|
|
2025
Q4 | $1.44M | Buy |
6,313
+300
| +5% | +$68.3K | 0.62% | 39 |
|
|
2025
Q3 | $1.39M | Hold |
6,013
| – | – | 0.67% | 35 |
|
|
2025
Q2 | $1.12M | Sell |
6,013
-305
| -5% | -$56.7K | 0.57% | 37 |
|
|
2025
Q1 | $1.32M | Hold |
6,318
| – | – | 0.71% | 34 |
|
|
2024
Q4 | $1.12M | Hold |
6,318
| – | – | 0.55% | 40 |
|
|
2024
Q3 | $1.25M | Sell |
6,318
-225
| -3% | -$42K | 0.62% | 40 |
|
|
2024
Q2 | $1.12M | Buy |
6,543
+735
| +13% | +$122K | 0.55% | 42 |
|
|
2024
Q1 | $1.06M | Sell |
5,808
-735
| -11% | -$127K | 0.6% | 40 |
|
|
2023
Q4 | $1.01M | Sell |
6,543
-75
| -1% | -$10.9K | 0.64% | 41 |
|
|
2023
Q3 | $986K | Hold |
6,618
| – | – | 0.72% | 41 |
|
|
2023
Q2 | $892K | Buy |
6,618
+75
| +1% | +$11K | 0.63% | 43 |
|
|
2023
Q1 | $1.04M | Sell |
6,543
-30
| -0.5% | -$4.59K | 0.81% | 35 |
|
|
2022
Q4 | $1.06M | Hold |
6,573
| – | – | 0.91% | 31 |
|
|
2022
Q3 | $882K | Hold |
6,573
| – | – | 0.79% | 37 |
|
|
2022
Q2 | $1.01M | Hold |
6,573
| – | – | 0.81% | 34 |
|
|
2022
Q1 | $1.07M | Hold |
6,573
| – | – | 0.68% | 42 |
|
|
2021
Q4 | $890K | Sell |
6,573
-223
| -3% | -$26.3K | 0.46% | 67 |
|
|
2021
Q3 | $733K | Sell |
6,796
-200
| -3% | -$22.9K | 0.39% | 80 |
|
|
2021
Q2 | $788K | Buy |
6,996
+189
| +3% | +$21.3K | 0.42% | 78 |
|
|
2021
Q1 | $737K | Hold |
6,807
| – | – | 0.44% | 80 |
|
|
2020
Q4 | $729K | Sell |
6,807
-5
| -0.1% | -$480 | 0.46% | 75 |
|
|
2020
Q3 | $597K | Sell |
6,812
-225
| -3% | -$21.2K | 0.44% | 73 |
|
|
2020
Q2 | $691K | Sell |
7,037
-379
| -5% | -$33.4K | 0.58% | 54 |
|
|
2020
Q1 | $565K | Buy |
7,416
+275
| +4% | +$23.4K | 0.57% | 59 |
|
|
2019
Q4 | $632K | Hold |
7,141
| – | – | 0.48% | 70 |
|
|
2019
Q3 | $541K | Sell |
7,141
-1,105
| -13% | -$75.8K | 0.45% | 80 |
|
|
2019
Q2 | $600K | Buy |
8,246
+325
| +4% | +$25.5K | 0.49% | 71 |
|
|
2019
Q1 | $638K | Sell |
7,921
-1,325
| -14% | -$108K | 0.55% | 66 |
|
|
2018
Q4 | $852K | Sell |
9,246
-320
| -3% | -$28.1K | 0.85% | 43 |
|
|
2018
Q3 | $905K | Sell |
9,566
-98
| -1% | -$9.29K | 0.75% | 47 |
|
|
2018
Q2 | $895K | Buy |
9,664
+425
| +5% | +$41.5K | 0.79% | 44 |
|
|
2018
Q1 | $874K | Buy |
9,239
+215
| +2% | +$23.6K | 0.82% | 42 |
|
|
2017
Q4 | $873K | Buy |
+9,024
| New | +$850K | 0.85% | 39 |
|
|
2013
Q3 | $195K | Sell |
5,114
-81
| -2% | -$3.59K | 0.25% | 105 |
|
|
2013
Q2 | $182K | Buy |
+5,195
| New | +$227K | 0.26% | 94 |
|
Other funds holding ABBV
VCM
VPM
AFT Forsyth & Company's ABBV Position: Q1 2026 in Review
AFT Forsyth & Company held its AbbVie (ABBV) position steady in Q1 2026 at 6,313 shares worth $1.37M. The position accounts for 0.65% of the portfolio, ranked #37.
AFT Forsyth & Company first reported a position in ABBV in Q2 2013 and has held it in 36 quarters since. The position peaked at $1.44M in Q4 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- AFT Forsyth & Company held 6,313 shares of AbbVie worth $1.37M as of Q1 2026.
- AFT Forsyth & Company left its AbbVie share count unchanged in Q1 2026.
- AbbVie made up 0.65% of AFT Forsyth & Company's portfolio in Q1 2026, its #37 holding.
- AFT Forsyth & Company first reported a position in AbbVie in Q2 2013 and has held it in 36 quarters since.
- AFT Forsyth & Company's AbbVie position peaked at $1.44M in Q4 2025.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on AFT Forsyth & Company's 13F filing for Q1 2026, filed 14 May 2026.